Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02169791 · ClinicalTrials.gov registry record · Phase 2
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
A Phase 2 study, sponsored by Northside Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT02169791 is a Phase 2 study that has completed, run by Northside Hospital. The registered enrollment target is 29 participants.
The verdict
NCT02169791, a Phase 2 study, has completed, sponsored by Northside Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
In an attempt to reduce relapse risk and improve outcomes following haploidentical transplantation for patients with high risk hematologic malignancies, the investigators will implement several strategies to augment the well documented effect of NK cell alloreactivity seen in HLA-mismatched transplantation. These strategies include (1) choosing potential haploidentical donors for optimal NK-alloreactivity, (2) utilizing proteasome inhibition post-transplant with MLN9708 to both sensitize tumor cells to NK cytotoxicity and protect against graft-versus-host disease (GVHD), and (3) eliminating mycophenolate mofetil from the post-transplant immunosuppression regimen to improve NK cell reconstitution following haploidentical peripheral blood stem cell transplantation.
Interventions
- DRUG MLN9708
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2014-07-15 |
| Est. Completion | 2020-07-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02169791
The ClinicalTrials.gov registry entry for NCT02169791 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northside Hospital, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MLN9708 is the first listed.
NCT02169791 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02169791 about?
NCT02169791 is a clinical study titled "Nonmyeloablative Haploidentical Transplant Followed by MLN9708". In an attempt to reduce relapse risk and improve outcomes following haploidentical transplantation for patients with high risk hematologic malignancies, the investigators will implement several strategies to augment the well documented effect of NK cell alloreactivity seen in HLA-mismatched transpla...
What is the current status of trial NCT02169791?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2014-07-15. Estimated completion is 2020-07-28.
What interventions are being tested in trial NCT02169791?
The interventions under investigation include: MLN9708 (DRUG).
Who is sponsoring clinical trial NCT02169791?
This trial is sponsored by Northside Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.